Close menu




January 19th, 2023 | 11:24 CET

Nel after the ITM Power shock: Better to bet on BioNTech and Alpina Holdings?

  • Technology
  • Investments
Photo credits: Nel ASA

The year 2022 was not the year of growth stocks. Will this change in 2023? The positive start to the current year shows that the chances of this happening are quite good; however, not in the hydrogen sector. The renewed warning from ITM Power is weighing on the entire sector and stoking fears that Nel, Plug Power & Co. will not be able to work off their full order books in 2023 either. That is where a look at other sectors and stocks can pay off. Example: Alpina Holdings from Singapore. The Company is growing at double-digit rates, and its valuation is incredibly low. BioNTech wants to expand further. Goldman Sachs expects strong newsflow from the cancer pipeline in 2023.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: NEL ASA NK-_20 | NO0010081235 , BIONTECH SE SPON. ADRS 1 | US09075V1026 , ALPINA HOLDINGS LIMITED | SGXE21011833

Table of contents:


    Alpina Holdings: Stock market newcomer with spectacularly favorable valuation

    Companies that are new to the stock market do not have to have a well-known brand name or a spectacular business model; they have to earn the attention of investors. Sometimes this takes more time than expected. This is the only way to explain Alpina Holdings' share price and valuation. The Company has been listed on the Singapore Exchange since 2022 and is now also listed on the Frankfurt Stock Exchange. The business model is anything but new but has been proven and profitable for years.

    The Company has been active as a real estate and construction services company in Singapore for 17 years and is thus active in one of the world's most attractive real estate markets. The business model is diversified around real estate and includes integrated building services (IBS), mechanical and electrical (M&E) engineering services and alterations and additions (A&A) for public and private sector projects. The majority of customers are from the public sector. The IBS segment, in particular, is characterized by growth and multi-year contracts. In 2021, Alpina turned over EUR 36.4 million, generating a profit of EUR 6.5 million. At a current share price of EUR 0.12, the market capitalization is around EUR 20 million, and as of June 30, 2022, the Company had cash and cash equivalents of around EUR 9 million. Even though a significant decline in earnings is expected for 2022 - due to the IPO costs, among other things - the valuation is still incredibly favorable. Moreover, management has already announced that for 2022 and 2023, at least 50% of profits will be distributed to shareholders in the form of a dividend.

    Alpina CEO Low Siong Yong said, "Going forward, we remain confident in the strength of our business model as an integrated facilities specialist. Coupled with our strong financial position, we also have the business flexibility to pursue attractive growth opportunities with differentiated offerings, such as our renewable energy project."

    Nel: Is ITM Power the exception?

    ITM Power's warning at the beginning of the week weighed on the entire hydrogen sector. While the UK company suffers from many homegrown problems, investors are still concerned that the entire industry is not getting the growth opportunity on the road. It is reminiscent of 2022 when the industry benefited from one stimulus package after another. Hydrogen - especially green - is seen virtually worldwide as a key pillar for the energy mix of the future. But operational performance, including from industry leaders such as Nel and Plug Power, has disappointed with low revenue growth and high losses. This is expected to change in 2023.

    We explain the situation at ITM Power: The UK-based electrolysis specialist has issued a revenue and profit warning for fiscal 2022/23 (ending April 30). Sales are expected to be lower, and the EBITDA loss is higher than expected. Reasons were previously unaccounted for delivery delays in customer contracts, additional costs, and write-downs on inventories. All problems are "surmountable," the Company said. "This is the challenge I expected when I came to ITM," said new CEO Dennis Schulz. "For the Company to evolve from an R&D and prototyping company to a mature delivery organization, we need a more solid foundation." Analysts at Berenberg were disappointed by this latest bad news. They said that the change of CEO was the right thing to do but that it would take time to realign the Company and regain lost trust. By way of background, the British company had already lowered its forecasts several times in 2022.

    Investors in other hydrogen companies, such as Nel ASA, are equally unsettled. Nel also had to contend with supply chain problems and lower-than-expected sales during the year. The Company also needs to finally get a handle on its high operating losses. Official Q4 2022 figures are due to be released on February 28. Following the recent industry shock, no analyst has yet commented on Nel. Jefferies recently raised its price target for the Norwegian stock from NOK 19 to NOK 20. The order books for 2023 are full. However, they must be processed efficiently.

    BioNTech: Goldman Sachs gives a price target of USD 177

    So far, the New Year's rally has passed BioNTech by. Investors can look forward to a lively news flow in the current year. Goldman Sachs also sees it that way and has renewed the price target of USD 177. The share is currently trading at just under USD 143. However, analysts still focus on the revenues from the COVID-19 vaccine, which are declining. Nevertheless, they point to the numerous upcoming study results on other infectious diseases and cancer. BioNTech's focus is on cancer research. The Mainz-based company's pipeline includes 19 product candidates in 24 ongoing clinical trials.

    However, BioNTech is currently somewhat overshadowed by Moderna. The US competitor plans to apply for approval for an RSV vaccine before the end of the first half of 2023. The Phase 3 trial is said to be promising. The study examined the vaccine's efficacy against RSV-related lower respiratory tract disease with two or more symptoms. The safety profile was said to be very good as well. About 37,000 people aged 60 and older from 22 countries participated in the study. BioNTech shareholders are now waiting for this kind of news.


    In the hydrogen sector, the wheat will be separated from the chaff in the current year. For a rising share price, Nel & Co. need increasing sales and at least - if no profits - decreasing losses. Alpina, a newcomer to the stock market, may be worth buying into. The business model is established, and the Company could develop into a dividend pearl. At BioNTech, shareholders are waiting for the first study results.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Nico Popp on January 25th, 2023 | 13:56 CET

    JinkoSolar, Volkswagen, Meta Materials: The growth stock that has it all

    • metamaterials
    • Innovations
    • Technology

    The media success of the AI tool ChatGPT has once again shown that innovations move people. The future is also in demand again on the stock market: growth companies are making significant gains and developing their own momentum. We present a company that can drive both innovative Greetech companies and long-established industrial stocks with its technology. The Company, listed on the Nasdaq, has nothing less than a revolution on offer. We will explain exactly what it is all about in three minutes.

    Read

    Commented by Armin Schulz on January 25th, 2023 | 13:48 CET

    Vonovia, Alpina Holdings, Commerzbank - Has the real estate market bottomed out?

    • Investments
    • RealEstate

    The past few years have been an El Dorado for the real estate sector. But since interest rates started rising, dark clouds have gathered over the real estate market. In addition, the sharp rise in construction costs and inflation are pulling money out of the pockets of interested real estate buyers and making them reluctant to make purchasing decisions. According to a study by EY Real Estate, the real estate investment market slumped by 40% in 2022. In 2023, transaction volumes could fall further. We take a look at three companies around the real estate sector and highlight the opportunities and risks.

    Read

    Commented by Stefan Feulner on January 23rd, 2023 | 10:11 CET

    Aurelius, Smartbroker Holding AG, Hypoport - Strong movements

    • Investments
    • Financial

    For years, the construction industry was booming. However, the sector slid into a deep crisis last year due to rising construction costs and the end of low interest rates. Experts are not yet giving the all-clear for the current year, either. The figures for online brokers were also down sharply. As a result, the share prices of the companies concerned plummeted. At a discounted level, this offers attractive entry opportunities for a company that should enjoy an absolutely unique selling proposition in the event of a successful launch of its new platform.

    Read